Dihydroartemisinin

Dihydroartemisinin has strong schizonticidal action, but has no effect on exoerythrocytic, sporogony and gametocyte fonns and is used as antimalarial drug. Dihydroartemisinin, is a drug with biological action of Artesunate and Artemether. Active mechanism of Dihydroartemisinin has not been known fully. Some researches suggest that the drug concentrates selectively into cells contracted by parasites and reacts with hemin (hemozoin), to kill the parasites. This reaction produces poisonous free radicals that can destroy membranes of parasites in vitro.

Brands
DIPIP DIPIP ARTEPIP NEO FANSIDAR NEO FANSIDAR ARMIQIN ARMIQIN ANTIMAL-RAPID ANTIMAL-RAPID ARTEQUINE ARTEQUINE TIMEQUIN TIMEQUIN DIMISINEX PARAQUIN
Adult Dose
Dose: 2 to 10 mg/Kg
Single Dose: 6 (6)
Frequency: 24 hourly
Route: PO
Instructions: It is available in combination with Pipraquine. Doses are calculated as mg/Kg/day. It is given for three days. Maximun 4 tablets each containing 40mg Dihydroartemisinin are indicated for upto 100 Kg weight patient. However, there are no data on which to base a dose recommendation in patients weighing >100kg.
Neonatal
Paedriatic
Characteristics
. It is of Semi Synthetic origin and belongs to Sesquiterpene lactone endoperoxide. . The Molecular Weight of Dihydroartemisinin is 284.35. Its pKa is 12.6.
Contraindications
Dihydroartemisinin
Effects
The severe or irreversible adverse effects of Dihydroartemisinin, which give rise to further complications include Neutropenia, ECG abnormalities, Prolongation of QI interval.The symptomatic adverse reactions produced by Dihydroartemisinin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Vomiting, Diarrhea, Arthralgia, Abdominal distress, Neutropenia, Pyrexia.
Indications
Dihydroartemisinin is primarily indicated in conditions like Malaria, Malaria caused by plasmodium falciparum.
Interactions
Dihydroartemisinin is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementMefloquine (HCl)Concomitant administration of mefloquine and dihydroartemisinin leads to a modest increase in mefloquine absorption rate.VORICONAZOLEVoriconazole may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
Drug should not be given to Pregnant Mothers.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
tablet Store at room temperature, Below -20°C. Protect from Heat.
Warnings
Do not take in first trimester of pregnancy and in children less then 5 Kg weight.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.